These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 28733631)
1. VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Zhang Y; Shen H; Withers HG; Yang N; Denson KE; Mussell AL; Truskinovsky A; Fan Q; Gelman IH; Frangou C; Zhang J Sci Rep; 2017 Jul; 7(1):6190. PubMed ID: 28733631 [TBL] [Abstract][Full Text] [Related]
2. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Lin Z; Guo H; Cao Y; Zohrabian S; Zhou P; Ma Q; VanDusen N; Guo Y; Zhang J; Stevens SM; Liang F; Quan Q; van Gorp PR; Li A; Dos Remedios C; He A; Bezzerides VJ; Pu WT Dev Cell; 2016 Nov; 39(4):466-479. PubMed ID: 27720608 [TBL] [Abstract][Full Text] [Related]
3. VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype. Mickle M; Adhikary G; Shrestha S; Xu W; Eckert RL Mol Carcinog; 2021 Jul; 60(7):497-507. PubMed ID: 34004031 [TBL] [Abstract][Full Text] [Related]
4. YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Lin C; Xu X Biomed Pharmacother; 2017 Nov; 95():789-794. PubMed ID: 28892790 [TBL] [Abstract][Full Text] [Related]
5. The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex. Zhang W; Xu J; Li J; Guo T; Jiang D; Feng X; Ma X; He L; Wu W; Yin M; Ge L; Wang Z; Ho MS; Zhao Y; Fei Z; Zhang L J Biol Chem; 2018 Nov; 293(44):17119-17134. PubMed ID: 30209132 [TBL] [Abstract][Full Text] [Related]
6. VGLL4 Protects against Oxidized-LDL-Induced Endothelial Cell Dysfunction and Inflammation by Activating Hippo-YAP/TEAD1 Signaling Pathway. Xu K; Zhao H; Qiu X; Liu X; Zhao F; Zhao Y Mediators Inflamm; 2020; 2020():8292173. PubMed ID: 33456372 [TBL] [Abstract][Full Text] [Related]
7. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis. Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor. Yao Y; Wang Y; Li L; Xiang X; Li J; Chen J; Liu Z; Huang S; Xiong J; Deng J J Cell Mol Med; 2019 Dec; 23(12):8076-8089. PubMed ID: 31559693 [TBL] [Abstract][Full Text] [Related]
9. TEAD mediates YAP-dependent gene induction and growth control. Zhao B; Ye X; Yu J; Li L; Li W; Li S; Yu J; Lin JD; Wang CY; Chinnaiyan AM; Lai ZC; Guan KL Genes Dev; 2008 Jul; 22(14):1962-71. PubMed ID: 18579750 [TBL] [Abstract][Full Text] [Related]
10. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Zhang W; Gao Y; Li P; Shi Z; Guo T; Li F; Han X; Feng Y; Zheng C; Wang Z; Li F; Chen H; Zhou Z; Zhang L; Ji H Cell Res; 2014 Mar; 24(3):331-43. PubMed ID: 24458094 [TBL] [Abstract][Full Text] [Related]
11. ACSL3 regulates breast cancer progression Tan S; Sun X; Dong H; Wang M; Yao L; Wang M; Xu L; Xu Y Cancer Biol Med; 2024 Jul; 21(7):606-35. PubMed ID: 38953696 [TBL] [Abstract][Full Text] [Related]
12. Multiple Roles of Vestigial-Like Family Members in Tumor Development. Yamaguchi N Front Oncol; 2020; 10():1266. PubMed ID: 32793503 [TBL] [Abstract][Full Text] [Related]
13. Hypermethylated in cancer 1 (HIC1) suppresses bladder cancer progression by targeting yes-associated protein (YAP) pathway. Zhou X; Zhang P; Han H; Lei H; Zhang X J Cell Biochem; 2019 Apr; 120(4):6471-6481. PubMed ID: 30417565 [TBL] [Abstract][Full Text] [Related]
14. YAP1-TEAD1 signaling controls angiogenesis and mitochondrial biogenesis through PGC1α. Mammoto A; Muyleart M; Kadlec A; Gutterman D; Mammoto T Microvasc Res; 2018 Sep; 119():73-83. PubMed ID: 29680477 [TBL] [Abstract][Full Text] [Related]
15. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. Chai J; Xu S; Guo F Biochem Biophys Res Commun; 2017 Jun; 488(2):297-302. PubMed ID: 28483529 [TBL] [Abstract][Full Text] [Related]
16. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311 [TBL] [Abstract][Full Text] [Related]
17. VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs. Deng X; Fang L Am J Cancer Res; 2018; 8(6):932-943. PubMed ID: 30034932 [TBL] [Abstract][Full Text] [Related]
18. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma. Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036 [TBL] [Abstract][Full Text] [Related]
19. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Zhi X; Zhao D; Zhou Z; Liu R; Chen C Am J Pathol; 2012 Jun; 180(6):2452-61. PubMed ID: 22632819 [TBL] [Abstract][Full Text] [Related]
20. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer. Kim JY; Kim EK; Lee WM; Hong YO; Lee H APMIS; 2020 Oct; 128(10):543-551. PubMed ID: 32794608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]